Share on StockTwits

Stock analysts at Cowen and Company boosted their target price on shares of Gilead Sciences (NASDAQ:GILD) from $80.00 to $95.00 in a report issued on Thursday, Stock Ratings News reports. Cowen and Company’s price objective points to a potential upside of 16.54% from the stock’s previous close.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 2.09% on Thursday, hitting $81.52. 10,163,842 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $39.24 and a 1-year high of $84.40. The stock’s 50-day moving average is $75.28 and its 200-day moving average is $67.00. The company has a market cap of $125.0 billion and a price-to-earnings ratio of 43.95.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $85.00 price target on the stock. Separately, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $95.00 to $132.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of Gilead Sciences from $91.00 to $97.00 in a research note to investors on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $82.54.

In other Gilead Sciences news, EVP Kevin Young sold 100,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $81.44, for a total value of $8,144,000.00. Following the completion of the transaction, the executive vice president now directly owns 216,418 shares of the company’s stock, valued at approximately $17,625,082. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.